ARIKACE™ Demonstrates Sustained Benefit In The Treatment Of Cystic Fibrosis Patients Who Have Pseudomonas Lung Infections
Originally posted in Cystic Fibrosis News From Medical News Today
Transave, Inc., reported interim results from a multi-cycle Phase II open label clinical trial in cystic fibrosis (CF) patients on its lead investigational drug, ARIKACE™ (liposomal amikacin for inhalation)…
by Raelene
